In this study, by developing a new form of targeted therapy we aimed to eliminate CD26+ CML LSCs/progenitor cells selectively and to reduce side effects on CD26− cells. This evidence concerns the gene DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive.